Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2016-11-04 Regulatory Filings
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-11-04 English
SCHEDULE 13D
Major Shareholding Notification
2016-11-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes detailed information about a merger transaction, changes in control, amendments to articles of incorporation, changes in directors and officers, and other significant corporate events. It also references various items typical of an 8-K filing such as entry into material definitive agreements, completion of acquisition or disposition of assets, changes in certifying accountant, and financial statements and exhibits. The document is not an annual or quarterly report, nor is it a transcript, earnings release, or proxy statement. It is a regulatory filing reporting significant corporate events and changes. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content support a high confidence in this classification.
2016-10-27 English
FORM 3
Director's Dealing
2016-10-26 English
FORM 3
Director's Dealing
2016-10-26 English
FORM 3
Director's Dealing
2016-10-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.